Damien Vasseur
A5075099274- Fibroblast Growth Factor Research
- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Eosinophilic Disorders and Syndromes
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Genetic factors in colorectal cancer
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Mast cells and histamine
- Ovarian cancer diagnosis and treatment
- Immune cells in cancer
- Epigenetics and DNA Methylation
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lymphoma Diagnosis and Treatment
- Metastasis and carcinoma case studies
- RNA modifications and cancer
- Renal cell carcinoma treatment
- Chromatin Remodeling and Cancer
- Pancreatic and Hepatic Oncology Research
- Endometrial and Cervical Cancer Treatments
- Peptidase Inhibition and Analysis
Dana-Farber Cancer Institute
2024-2025
Institut Gustave Roussy
2020-2024
Inserm
2020-2023
Université Paris-Saclay
2023
Centre National de la Recherche Scientifique
2023
Hôpital Lyon Sud
2019-2020
Hospices Civils de Lyon
2019-2020
Centre de Recherche en Cancérologie de Lyon
2019-2020
Lyon College
2019
Université Claude Bernard Lyon 1
2019
Abstract Several fibroblast growth factor receptor (FGFR) inhibitors are approved or in clinical development for the treatment of FGFR-driven urothelial cancer, and molecular mechanisms resistance leading to patient relapses have not been fully explored. We identified 21 patients with cancer treated selective FGFR analyzed postprogression tissue and/or circulating tumor DNA (ctDNA). detected single mutations tyrosine kinase domain seven (33%) (FGFR3 N540K, V553L/M, V555L/M, E587Q; FGFR2...
Nearly 1% to 2% of NSCLCs harbor RET fusions. Characterization this rare population is still incomplete.This retrospective multicenter study included patients with any-stage positive (RET+) NSCLC from 31 cancer centers. Molecular profiling DNA/RNA sequencing or fluorescence in situ hybridization analyses. Clinicobiological features and treatment outcomes (per investigator) surgery, chemotherapy (CT), immune checkpoint blockers (ICBs), CT-ICB, multityrosine kinase inhibitors, inhibitors...
PURPOSE High-risk clonal hematopoiesis (CH) is frequently incidentally found in patients with solid tumors undergoing plasma cell–free DNA sequencing. Here, we aimed to determine if the incidental detection of high-risk CH by liquid biopsy may reveal occult hematologic malignancies tumors. MATERIALS AND METHODS Adult advanced cancers enrolled Gustave Roussy Cancer Profiling study (ClinicalTrials.gov identifier: NCT04932525 ) underwent at least one (FoundationOne Liquid CDx). Molecular...
Abstract Purpose: Understanding resistance to selective FGFR inhibitors is crucial improve the clinical outcomes of patients with FGFR2-driven malignancies. Experimental Design: We analyzed sequential ctDNA, ± whole-exome sequencing, or targeted next-generation sequencing on tissue biopsies from tumors harboring activating FGFR2 alterations progressing pan-FGFR–selective inhibitors, collected in prospective UNLOCK program. FGFR2::BICC1 Ba/F3 and patient-derived xenograft models were used for...
•Clonal architecture of molecular alterations at the cellular level depicts cancer cell adaptation during targeted therapy.•Single-cell sequencing from patient biopsies revealed coexistence two driver within single cells.•Pharmacological evaluation in patient-derived models asserts need for simultaneous inhibition each driver. BackgroundThe development agents, such as osimertinib EGFR-mutated non-small-cell lung (NSCLC), has drastically improved outcome, but tumor resistance eventually...
<p>supplementary materials</p>
<div>AbstractPurpose:<p>This study aimed to explore metabolic tumor volume (MTV) as assessed by 18F-fluorodeoxyglucose positron emission tomography–computed tomography (18F-FDG–PET/CT) and understand its biological meaning in patients with non–small cell lung cancer (NSCLC) exposed immune checkpoint blockers (ICB).</p>Experimental Design:<p>In this study, advanced NSCLC a positive PET scan within 42 days of first-line treatment were enrolled 11 institutions across...
(Abstracted from Cancer 2024;130(19):3311–3320) Endometrial cancer (EC) has been increasing in incidence and mortality rates due to increased prevalence of risk factors such as obesity, metabolic syndrome, diabetes. Many cases are treatable through a combination methods, but up 20% detected at an advanced stage, which grim prognosis.
539 Background: Clear cell renal carcinoma (ccRCC) with sarcomatoid differentiation (sRCC) is associated poor survival. Recent studies have shown downregulation of hypoxia-related pathways in sRCC (Motzer et al., Cancer Cell, 2020; El Zarif, Semaan Cell Reports, 2024). In this study, we sought to compare HIF2α expression levels ccRCC, and without investigate clinical outcomes patients (pts) treated inhibitors (HIF2αi). Methods: To assess gene sRCC, RNA-seq data was collected from 2 trials:...
Abstract Oncogenic translocations involving the MET gene have been reported in several cancer types, but detailed clinicogenomic characterization of these cancers is not well defined. In addition, prospective clinical trials evaluating antitumor activity inhibitors rearrangement-positive are limited. Here, a pan-cancer analysis &gt;46,000 solid tumors with comprehensive genomic profiling, we identified oncogenic rearrangements ~0.04% cancers. Preliminary from phase 2 trial type I...
Next-generation sequencing (NGS) assays based on plasma cell-free DNA (cfDNA) are increasingly used for clinical trials inclusion. Their optimized limit of detection applied to a large number genes leads the identification mutations not confirmed in tissue. It becomes essential describe characteristics and consequences these liquid biopsy-only mutations. In STING protocol (Gustave Roussy, NCT04932525), 542 patients with advanced solid cancer had cfDNA-based tissue-based NGS analysis...
Tumor fraction at liquid biopsy was weakly correlated with the total tumor volume contrast-enhanced CT and did not accurately reflect burden CT.
PURPOSE With liquid biopsy's widespread adoption in oncology, an increased number of clonal hematopoiesis–associated mutations (CHm) have been identified patients with solid tumors. However, its impact on patient outcomes remains unclear. This study aimed to analyze and describe CHm a cohort phase I patients. METHODS Retrospective data collection from medical records molecular profiles (Foundation One Liquid CDx Assay) was performed before first drug administration at the Drug Development...
Molecular characterization has significantly improved the management of advanced endometrial cancer (EC). It distinguishes four molecular subclasses associated with prognosis and personalized therapeutic strategies. This study assesses clinical utility cell-free DNA (cfDNA) profiling in EC to identify targetable alterations.
Knowing the homologous recombination deficiency (HRD) status in advanced epithelial ovarian cancer (EOC) is vital for patient management. HRD determined by BRCA1/BRCA2 pathogenic variants or genomic instability. However, tumor DNA analysis inconclusive 15-19% of cases. Peritoneal fluid, available > 95% EOC cases, could serve as an alternative source cell-free (cftDNA) testing. Limited data show feasibility panel gene testing on ascites cfDNA but no study, to date, has investigated testing.We...
5577 Background: HRD testing at diagnosis is crucial for patients with advanced high grade OC (HGOC). status defined by a BRCA1 or BRCA2 pathogenic variant, genomic instability score (GIS). These tests are performed on tumor samples but result in non-contributive 10-19% of cases. We have previously shown that ascites yields quality derived cell-free DNA (cfDNA) suitable testing. Here we present results from an updated prospective series (BRCAm+/-GIS) 20ml peritoneal fluid obtained diagnostic...
ROS1 tyrosine kinase inhibitors (TKIs) have showed activity and efficacy in ROS1-rearranged non-small cell lung cancer (NSCLC). In the clinical practice, besides utilization of crizotinib, less is known about best treatment strategies involving additional, new-generation TKIs for sequential ROS1-positive NSCLC patients.A patient suffering from a adenocarcinoma, after receiving cisplatin-pemetrexed chemotherapy, was treated with entrectinib, ALK/ROS1/NTRK inhibitor. After 16 months, central...